David Fajgenbaum, MD, MBA, of the University of Pennsylvania, talks about his research efforts to find an already-approved drug that could treat his orphan disease—multicentric Castleman disease—and how that methodology may be applied to the coronavirus and the cytokine storm it can cause (Symposium 5).
Toni K. Choueiri, MD, of Dana-Farber Cancer Institute, discusses the challenges of delivering optimal cancer treatments in the face of the coronavirus pandemic. Focusing on systemic therapies, he reviews prognostic factors in people with cancer and COVID-19 (Symposium 9).
Antoni Ribas, MD, PhD, of the University of California, Los Angeles and Jonsson Comprehensive Cancer Center, and President of the American Association for Cancer Research, talks about why the meeting was held, how the coronavirus has affected cancer care and will impact long-term survivorship, as well as health-care disparities and changes to clinical trials.
Giuseppe Curigliano, MD, PhD, of the University of Milan and Istituto Europeo Oncologico, talks about designing public health measures focused on COVID-19 morbidity and mortality for cancer patients, defining treatment and vaccine priorities, and creating a model to assess the impact of control measures (Symposium 6).
